CLINICAL_TRIALS
trial_result
· 2020-07-07
Clinical Trial Update: Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation [Phase 2]
Summary
Phase 2 trial update investigating adjuvant afatinib in stage I-III non-small cell lung cancer with EGFR mutation.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN